KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Sep 2025 value amounting to $251.1 million.

  • Alnylam Pharmaceuticals' Net Income towards Common Stockholders rose 325.05% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 113.11%. This contributed to the annual value of -$278.2 million for FY2024, which is 36.82% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Net Income towards Common Stockholders is $251.1 million, which was up 478.84% from -$66.3 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Net Income towards Common Stockholders registered a high of $251.1 million during Q3 2025, and its lowest value of -$405.9 million during Q3 2022.
  • Its 3-year average for Net Income towards Common Stockholders is -$53.7 million, with a median of -$66.3 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Alnylam Pharmaceuticals' Net Income towards Common Stockholders was 325.05% (2025), while the steepest drop was 292.43% (2025).
  • Alnylam Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$258.5 million in 2021, then rose by 19.72% to -$207.5 million in 2022, then skyrocketed by 33.55% to -$137.9 million in 2023, then surged by 39.24% to -$83.8 million in 2024, then surged by 325.05% to $251.1 million in 2025.
  • Its last three reported values are $251.1 million in Q3 2025, -$66.3 million for Q2 2025, and -$57.5 million during Q1 2025.